Home › Oropharyngeal Cancer › Texas
Oropharyngeal Cancer clinical trials in Texas
6 studies for Oropharyngeal Cancer are looking for participants at sites in Texas.
Cities in Texas
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- M D Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT01365169SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
- UT MD Anderson - The Woodlands, Conroe
- UT MD Anderson Cancer Center, Houston
- UT MD Anderson - West Houston, Houston
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT05451004High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 26, 2026 · NCT04151082Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT03010150Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- Baylor College of Medicine, Houston
Recruiting
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT05793151From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.